Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population?

International Journal of Urology

Volumn 19, Issue 8, 2012, Pages 749-756

  Liu, Yishan ^a,b   Vlatkovic, Ljiljana ^a   Sæter, Thorstein ^c   Servoll, Einar ^c   Waaler, Gudmund ^c   Nesland, Jahn M ^a,b   Giercksky, Karl Erik ^a,b   Axcrona, Karol ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c Sørlandet Sykehus ^*  (Norway)

Author keywords

B7 H3; Ki 67; Prostate cancer

Indexed keywords

CELL PROTEIN; KI 67 ANTIGEN; PROTEIN B7 H3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CELL POPULATION; CLINICAL FEATURE; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADULT; AGED; B7 ANTIGENS; CARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; PHENOTYPE; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84864299061     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.03017.x     Document Type: Article

References (21)

1. Pagès F, Galon J, Dieu-Nosjean M-C, Tartour E, Sautès-Fridman C, Fridman W-H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010; 29: 1093-102.
2. Müller-Hübenthal B, Azemar M, Lorenzen D etal. Tumour Biology: tumour-associated inflammation versus antitumor immunity. Anticancer Res. 2009; 29: 4795-805.
3. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411: 380-4.
4. Radoja S, Frey AB. Cancer-induced defective cytotoxic T lymphocyte effector function: another mechanism how antigenic tumors escape immune-mediated killing. Mol. Med. 2000; 6: 465-79.
5. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 2000; 74: 181-273.
6. Seliger B, Marincola FM, Ferrone S, Abken H. The complex role of B7 molecules in tumor immunology. Trends Mol. Med. 2008; 14: 550-9.
7. Yi KH, Chen L. Fine tuning the immune response through B7-H3 and B7-H4. Immunol. Rev. 2009; 229: 145-51.
8. Hashiguchi M, Kobori H, Ritprajak P, Kamimura Y, Kozono H, Azuma M. Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc. Natl. Acad. Sci. U.S.A. 2008; 105: 10495-500.
9. Sun X, Vale M, Leung E, Kanwar JR, Gupta R, Krissansen GW. Mouse B7-H3 induces antitumor immunity. Gene Ther. 2003; 10: 1728-34.
10. Luo L, Chapoval AI, Flies DB etal. B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J. Immunol. 2004; 173: 5445-50.
11. Mahnke K, Ring S, Johnson TS etal. Induction of immunosuppressive functions of dendritic cells in vivo by CD4+CD25+ regulatory T cells: role of B7-H3 expression and antigen presentation. Eur. J. Immunol. 2007; 37: 2117-26.
12. Wu C-P, Jiang J-T, Tan M etal. Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World J. Gastroenterol. 2006; 12: 457-9.
13. Crispen PL, Sheinin Y, Roth TJ etal. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin. Cancer Res. 2008; 14: 5150-7.
14. Roth TJ, Sheinin Y, Lohse CM etal. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 2007; 67: 7893-900.
15. Zang X, Thompson RH, Al-Ahmadie HA etal. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc. Natl. Acad. Sci. U.S.A. 2007; 104: 19458-63.
16. Tekle C, Nygren MK, Chen YW etal. B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes. Int. J. Cancer 2012; 130: 2282-90.
17. Kusmartsev S, Vieweg J. Enhancing the efficacy of cancer vaccines in urologic oncology: new directions. Nat. Rev. Urol. 2009; 6: 540-9.
18. Servoll E, Sæter T, Vlatkovic L, Nesland J, Waaler G, Beisland HO. Does a tertiary Gleason pattern 4 or 5 influence the risk of biochemical relapse after radical prostatectomy for clinically localized prostate cancer? Scand. J. Urol. Nephrol. 2010; 44: 217-22.
19. Epstein JI, Allsbrook WCJ, Amin MB, Egevad LL, Committee atIG. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am. J. Surg. Pathol. 2005; 29: 1228-42.
20. Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J. Urol. 1996; 156: 1064-8.
21. Rubio J, Ramos D, López-Guerrero JA etal. Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur. Urol. 2005; 48: 745-51.